EZH2 and breast carcinoma: Constitutive activation of NF‐κB and EZH2 overexpression have been documented in highly aggressive breast carcinomas and are correlated with clinico‐pathological features.28, 29, 30, 31, 32 In contrast, breast cancer cell lines demonstrating high metastatic potential possess low levels of NKILA transcript, consistent with its suggested anti‐tumoural function.25 We anticipated and observed an inverse association between EZH2 expression and NKILA transcript levels, with respective high/low expression in breast cancer cells characterized by constitutively active NF‐κB and high EZH2 expression.